Aviva
CPRX

Aviva’s Catalyst Pharmaceutical CPRX Stock Holding History

Aviva’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$470K Sell
18,963
-2,033
-10% -$48.4K ﹤0.01% 707
2025
Q4 		$490K Sell
20,996
-3,129
-13% -$69.7K ﹤0.01% 775
2025
Q3 		$475K Buy
24,125
+4,557
+23% +$93.7K ﹤0.01% 778
2025
Q2 		$425K Sell
19,568
-7,868
-29% -$186K ﹤0.01% 845
2025
Q1 		$665K Sell
27,436
-724
-3% -$16.3K ﹤0.01% 649
2024
Q4 		$588K Sell
28,160
-3,719
-12% -$79.9K ﹤0.01% 715
2024
Q3 		$634K Sell
31,879
-7,303
-19% -$135K ﹤0.01% 770
2024
Q2 		$607K Sell
39,182
-1,975
-5% -$30.7K ﹤0.01% 771
2024
Q1 		$656K Sell
41,157
-1,977
-5% -$29.8K ﹤0.01% 765
2023
Q4 		$725K Buy
+43,134
New +$590K ﹤0.01% 725
2022
Q1 		– Sell
-386,085
Closed -$2.61M – 1070
2021
Q4 		$2.61M Buy
386,085
+59,700
+18% +$393K 0.01% 769
2021
Q3 		$1.73M Buy
+326,385
New +$1.78M 0.01% 787

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Aviva's CPRX Position: Q1 2026 in Review

Aviva reduced its Catalyst Pharmaceutical (CPRX) stake by 9.7% in Q1 2026, selling an estimated $48.4K and leaving 18,963 shares worth $470K. The position accounts for ﹤0.01% of the portfolio, ranked #707.

Aviva first reported a position in CPRX in Q3 2021 and has held it in 12 quarters since. The position peaked at $2.61M in Q4 2021. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Aviva held 18,963 shares of Catalyst Pharmaceutical worth $470K as of Q1 2026.
  • Aviva sold 2,033 Catalyst Pharmaceutical shares in Q1 2026, an estimated $48.4K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Aviva's portfolio in Q1 2026, its #707 holding.
  • Aviva first reported a position in Catalyst Pharmaceutical in Q3 2021 and has held it in 12 quarters since.
  • Aviva's Catalyst Pharmaceutical position peaked at $2.61M in Q4 2021.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Aviva's 13F filing for Q1 2026, filed 14 May 2026.